Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Drops By 12.3%

GeoVax Labs, Inc. (NASDAQ:GOVX) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 610,600 shares, a decrease of 12.3% from the February 28th total of 696,400 shares. Based on an average trading volume of 678,200 shares, the short-interest ratio is currently 0.9 days. Approximately 6.9% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Citadel Advisors LLC acquired a new stake in GeoVax Labs during the 4th quarter valued at $104,000. Virtu Financial LLC purchased a new stake in shares of GeoVax Labs in the third quarter valued at $97,000. Geode Capital Management LLC lifted its position in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares in the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of GeoVax Labs during the fourth quarter valued at $29,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, D. Boral Capital reissued a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a report on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, GeoVax Labs currently has an average rating of “Buy” and an average price target of $14.20.

GeoVax Labs Price Performance

GOVX opened at $1.08 on Wednesday. The stock’s 50 day simple moving average is $1.62 and its 200 day simple moving average is $2.10. The stock has a market cap of $10.19 million, a P/E ratio of -0.19 and a beta of 3.06. GeoVax Labs has a 1-year low of $1.03 and a 1-year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.49. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.38 million. Research analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.